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The combined procedure was diagnostic in 67% of the patients(52/67)
Conclusions: EBUS TBNA and EUS FNA is both effective and non 
invasive methods to obtain a diagnose in patients with lesions of un-
known origin in the lungs and mediastinum
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Objective: The aim of the present study was to compare the results 
from EBUS-TBNA with standard medi-astinoscopy in the evaluation of 
mediastinal lymph nodes in patients with lung cancer or undiag-nosed 
solid lesion in the mediastinum 
Methods: The combination of EBUS TBNA and mediastinoscopy was 
prospective performed in 66 patients during the same general anaesthe-
sia.
Results: A total of 66 patients (29 females and 37 males mean age 60 
years) underwent EBUS TBNA and Mediastinoscopy combined. 
I 61 patients (93%) EBUS TBNA the result was consistent with the 
ﬁnal diagnose and the medi-astnoscopy was correct in 53 patients 
(80%). In one patient both mediastinoscopy and EBUS TBNA was 
false negative.
The ﬁnal diagnose for the patients were 55 cancers, 1 tuberculosis. 1 
lymphoma, 3 sarcoidosis and 6 inﬂamations.
NPV and PPV for the two methods will be discussed.
Conclusions: EBUS-TBNA is an accurate, safe and minimally invasive 
diagnostic technique for the staging of mediastinal lymph nodes. It’s 
routine use for this purpose instead of mediastinoscopy should be 
considered 
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Background: Early and precise response evaluation is of great value 
in patients (pts) with advanced/metastatic NSCLC in order not only to 
reduce toxicity and additional cost by ineffective and unnecessary toxic 
treatment but also to get a chance to receive other possible effective 
treatments earlier. We conducted a prospective study to evaluate 18-
ﬂuorodeoxyglucose positron emission tomography-computed tomogra-
phy (PET-CT) for early prediction of response and survival.
Methods: Between May 2004 and November 2005, 31 pts [gender, 
23M, 8F; stage, 2IIIB, 29IV, histology, 6 squamous cell ca, 22 adenoca, 
3 NOS; age, median 57 (30-73 yr)] with pathologically proven NSCLC 
stage IIIB/IV participated into this study. PET response or metabolic 
response was measured prospectively according to recommendations of 
the EORTC PET study group after one cycle of treatment. Radiologic 
response or best overall response was determined according to WHO 
response criteria every 3 cycles or when clinically indicated.
Results: Pts underwent systemic treatment with gemcitabine/vinorel-
bine (15), gemcitabine/cisplatin (1) gemcitabine/vinorelbine/cisplatin 
(1), irinotecan/cisplatin (9) or geﬁtinib (5). Out of 31 pts, there were 
12 PRs (38.7%), 5 SDs and 14 PDs. Out of 13 progressive metabolic 
diseases (PMD), there were 9 PRs, 3 SDs and 1 PR, while all of 7 
partial metabolic responses (PMR) were conﬁrmed to reach PR. When 
increased pleural effusion identiﬁed on PET-CT was deﬁned as PMD, 
there were 17 PMDs, of which there were 13 PDs, 2 SDs and 2 PR. 
As radiologic response was signiﬁcantly correlated with time-to-pro-
gression and survival time (p<0.001 and p=0.015, respectively), early 
metabolic response was signiﬁcantly correlated with them (p<.0.001 
and p=0.031, respectively).
Conclusions: FDG-PET-CT can predict early he best response to 
treatment. Therefore, the early use of FDG-PET-CT can reduce side 
effects and costs of ineffective therapy in non-responding patients and 
may early predict response to new therapeutic agents. However, the 
patients showing equivocal metabolic response will be reassessed by 
subsequent response evaluation. Our study needs to be validated in a 
larger series.
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Background: Lung cancer is rarely found in young patients, especially 
in those younger than 40 years of age. It has been suggested that the 
clinical features, pathologic ﬁndings, and prognosis in young patients 
with lung cancer differ from those in elderly patients with lung cancer. 
The aim of this study was to describe the CT features of lung cancer in 
patients under the age of 40.
Methods: We retrospectively reviewed demographic ﬁndings, histol-
ogy and staging of lung cancer under the age of 40 years among 6,876 
patients who were diagnosed to have primary lung cancer at our hos-
pital during the period from 2001 to 2006. CT ﬁndings were retrospec-
tively assessed in terms of the location (peripheral or central), shape 
(mass or consolidation) and size of primary tumor, presence of pleural 
or pericardial effusion and pleural nodules and pattern of lung metas-
tasis [micronodular (< 5mm), macronodular (≥ 5mm), or lymphangitic 
metastasis].
Results: Primary lung cancer was diagnosed in 132 patients (1.9%). 
They were 70 men and 62 women with mean age of 34 years (range 13 
- 39 years). One hundred patients (76%) had adenocarcinoma; 11 (8%), 
non small cell carcinoma-not otherwise speciﬁed; 9 (7%), squamous 
cell carcinoma; 8 (6%), small cell carcinoma; 2 (2%), adenosquamous 
cell carcinoma; and one each (1%), sarcomatoid carcinoma and muco-
epidermoid carcinoma. At the time of diagnosis 9 (7%) had stage I, 1 
(1%) stage II, 30 (23%) stage III, and 92 (70%) stage IV. 
In 117 patients, 50 lesions were located in central and 67 were in 
peripheral. Fifteen lung cancers were consolidation type. The longest 
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diameter of primary mass was ranging from 10 to 119 mm (mean ± SD, 
44 ± 22 mm). Pleural or pericardial effusion was identiﬁed on 58 cases 
and pleural nodules without pleural effusion suggesting dry pleural 
seeding were identiﬁed in 8 cases. Pulmonary metastasis was found in 
74 patients (56%) showing micronodular in 27 cases, macronodular 
in 23 cases and lymphangitic carcinomatosis in 44 cases. Thirty-one 
of the 74 patients with pulmonary metastases showed unilateral lung 
metastases. Only 34 of the 132 patients showed no evidence of distant 
metastases. 
Conclusion: The majority of lung cancer under age 40 was adenocar-
cinoma and stage IV. Although we could not ﬁnd speciﬁc radiologic 
features, unilateral pulmonary metastasis was common in this age 
group. This study suggested that young patients under age 40 with lung 
cancer often present with unilaterally advanced disease.
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Background: Cavitation within lung tumors, either spontaneous or 
secondary to chemotherapy, has been documented by several reports. 
However, to our knowledge, there have been few reports of radiologic 
ﬁndings of cavitary change of miliary pulmonary metastases follow-
ing chemotherapy. The aim of this study was to describe CT ﬁndings 
of thin walled cavitary changes of miliary pulmonary metastases from 
primary lung cancer following chemotherapy.
Methods: Between 2001 and 2006, six patients (male-female ratio, 3:3; 
mean age, 53 years; age range, 44-63 years) with thin-walled cavitary 
change of miliary pulmonary metastases from primary lung cancer 
following chemotherapy were identiﬁed at our hospital. We deﬁned 
thin wall as less than 5-mm in wall thickness of nodule. We retrospec-
tively reviewed histology of primary lung cancer and chemotherapeutic 
agents for treatment. CT ﬁndings were assessed in terms of the relation-
ship of cavity with metastatic nodules, change of size of nodule and 
cavity, and parenchymal change. 
Results: The histology of primary lung cancer was adenocarcinoma 
in all patients. The patients were treated with a variety of chemothera-
peutic agents (irinotecan, cisplatin, gemcitabine, navelbine, taxotere, 
iressa, etc). Primary lung cancer with diameters ranging from 27 to 80 
mm (mean ± SD, 55 ± 21 mm), were identiﬁed in 5 patients. Cavitary 
changes of primary lung cancer prior to chemotherapy were found in 3 
of the 5 patients.
Thin walled cavitary change of pulmonary metastases after chemo-
therapy was identiﬁed on 6 cases. The thin-walled cavity was located 
within the preexisting metastatic pulmonary nodule (n=3) and adjacent 
to the preexisting metastatic pulmonary nodule (n=3). The cavity was 
markedly increased in size on follow-up CT scans in 2 patients with 
underlying emphysema and no signiﬁcant change in 4 patients. The 
shape of the cavity of pulmonary metastases was round (n=1) or irregu-
lar (n=5). The size of the cavity of pulmonary metastases was uniform 
(n=1) or various (n=5). Two of the six patients showed structural distor-
tion of lung parenchyma on follow-up CT scans after chemotherapy.
Conclusions: Thin-walled cavitary change of pulmonary metastases 
from primary lung cancer following chemotherapy was identiﬁed and 
the cavities were located inside or adjacent to preexisting metastatic 
nodule. Marked increase in size of the cavity and structural distortion 
of lung parenchyma on follow-up CT after chemotherapy were founded 
in 2 patients. These CT ﬁndings support the previously reported mecha-
nisms of cavitary change of pulmonary nodules: necrosis of the tumor 
metastases, check-valve mechanism and cystic dilatation of bronchus 
due to ﬁbrotic change of healing peribronchial nodules. 
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Computed tomography-guided transthoracic needle biopsy in 
diagnosing lung lesions
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Background: To assess the clinical value of computed topography 
(CT) guided transthoracic needle aspiration (TTNA) in pulmonary 
lesions. 
Methods: To summarize 50 patients with lung lesions who underwent 
surgery, before that we performed TTNA, then analyzed its’ sensitivity, 
speciﬁcity and complications. 
Result: We got tissue in each case successfully among them 40 were 
malignant (17 squamous carcinoma,14 adenocarcinoma, 3 small cell 
lung cancer,6 undeﬁned carcinoma), 10 bingn. All were testiﬁed by 
surgery 10 infections or normal lung tissue turned to be false negative 
in 5 cases,sensitivity 88.8%,speciﬁsity100%. 5 had complications of 
pneumothorax, 1 of them underwent closed drainage, 5 got coughing 
up blood, however recoverd rapdliy after hemostatic treatmnet. 
Conclusion: CT guided transthoracic needle aspiration is a easy,safe 
and reliable method for lung lesions diagnosis.
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Background: To retrospectively investigate and compare the useful-
ness of trans-thoracic ﬁne needle aspiration (FNA) and core needle 
biopsy (CNB) in the diagnosis of pulmonary lesions. 
Methods: Sixty-nine consecutive CT-guided lung biopsies were per-
formed in 60 patients between Dec 1998 and Dec 2005 and 30 patients 
underwent CNB (with an automated 18-G core biopsy needle and a 
gun) and FNA (with a 22-G needle) procedures respectively, either 
ﬁne-needle aspirate samples for cytology or core biopsy samples for 
histology were collected. Of these, a ﬁnal diagnosis was obtained in 
all lesions with surgery, then analyzed its’ sensitivity, speciﬁcity and 
complications. 
Results: Core biopsy yielded a correct diagnosis was obtained in 25 
procedures (89.3%) for malignant leisons. Aspiration biopsy yielded 
a correct diagnosis in 24 procedures (88.8%) for malignant leisons. 
Pneumothorax occurred in 4/30 (13.3%) patients with core biopsy and 
in 2/30(6.6%) patients with aspiration biopsy. Of these, one with core 
biopsy needed tube drainage. The other complication was haemoptysis, 
which occurred in ﬁve patients following core biopsy and in two after 
aspiration biopsy. All seven cases subsided spontaneously. There were 
no fatal complications.
